Trials / Conditions / EBV-Positive DLBCL, Nos

EBV-Positive DLBCL, Nos

8 registered clinical trials studyying EBV-Positive DLBCL, Nos — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019	Schrödinger, Inc.	Phase 1
Active Not Recruiting	Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas NCT05583149	Patrick C. Johnson, MD	Phase 2
Terminated	An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymp NCT05011058	Viracta Therapeutics, Inc.	Phase 2
Unknown	Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL NCT04796857	Huiqiang Huang	Phase 1 / Phase 2
Unknown	Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL NCT04705129	Ruijin Hospital	Phase 2
Unknown	Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL NCT04476459	Huiqiang Huang	Phase 1 / Phase 2
Unknown	Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma NCT04058470	Huiqiang Huang	Phase 1 / Phase 2
Unknown	Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS NCT04181489	The First Affiliated Hospital with Nanjing Medical University	Phase 2